涉内幕交易，贵州百灵实控人姜伟被立案

Core Viewpoint - Guizhou Bailing announced that its actual controller, Jiang Wei, is under investigation by the China Securities Regulatory Commission (CSRC) for insider trading and information disclosure violations, which is unrelated to the company's operations and will not impact its business activities [1][4]. Company Overview - Guizhou Bailing is engaged in the research, production, and sales of traditional Chinese medicine, with a registered capital of 1.4112 billion yuan and total assets of 7.059 billion yuan. The company was listed on the Shenzhen Stock Exchange in June 2010 and aims to strengthen its position in the traditional Chinese medicine sector [4][3]. Financial Performance - For the first three quarters of 2025, Guizhou Bailing reported revenue of 2.102 billion yuan, a year-on-year decrease of 24.28%, and a net profit attributable to shareholders of 57 million yuan, down 35.60% year-on-year [5]. - The company experienced a significant decline in revenue and net profit in the first half of 2025, with revenue of 1.462 billion yuan, a decrease of 31.77%, and a net profit of 52 million yuan, down 40.73% year-on-year. The decline in revenue from traditional Chinese medicine products, which account for over 80% of total revenue, was particularly notable, with a year-on-year decrease of 37.07% [4][5]. - Despite a year-on-year increase in revenue and net profit in the third quarter, the overall performance for the first three quarters remained significantly lower due to poor results in the first half of the year [4].